Net Present Value Model: IMV Inc’s Maveropepimut-s
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Net Present Value Model: IMV Inc’s Maveropepimut-s report and make more profitable business decisions.
Empower your strategies with our Net Present Value Model: IMV Inc’s Maveropepimut-s report and make more profitable business decisions.
Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development.
Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
IMV Inc’s Maveropepimut-s Drug Details:
Maveropepimut-s (DPX-Survivac) is under development for the treatment of glioblastoma, ovarian cancer, fallopian tube cancer, bladder cancer, liver cancer (hepatocellular carcinoma), non-small cell lung (NSCLC) cancer as well as tumors shown to be positive for the microsatellite instability-high (MSI-H) biomarker, diffuse large B-cell lymphoma, peritoneal cancer and (HR+/HER2-) breast cancer. It is administered subcutaneously. It comprises survivin-based antigens formulated in the DepoVax delivery platform and DPX platform. It was also under development for the treatment of prostate cancer.
Report Coverage
GlobalData accounts for many factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high-value models that companies can use to help evaluate drugs and companies.
Scope
- Drug Name
- Administration Pathway
- Therapeutic Areas
- Key Manufacturers
- Drug Development Status
- Patent law
- Known and Projected regulatory approval processes
- Cash flows
- Potential applicable patients
- Drug margins
- Company expenses
- Pricing estimates
Reasons to Buy
- Obtain a better understanding of the quantitative value of Net Present Value Model: IMV Inc’s Maveropepimut-s.
- Access another data source to use in the valuation of Net Present Value Model: IMV Inc’s Maveropepimut-s
- Create or support internal NPV models to improve accuracy.
- Understand a drug’s expected profit, considering revenue and cost forecasts leveraging public and proprietary data sets.